Serious Ozempic Side Effects & Warnings

See if you qualify in 5 minutes →
5-minute questionnaire · reviewed by a licensed clinician · Nouri Promise: full refund in 30 days on 3-month and 6-month plans · cancel anytime

At a glance: serious warnings and red-flag symptoms

Warning	What it is	Red-flag signs — act on these
Thyroid C-cell tumors (boxed)	Rodent-study risk; human relevance not determined. Contraindicated with MTC/MEN 2 history.	Neck lump or swelling, hoarseness, trouble swallowing
Pancreatitis	Inflammation of the pancreas (labeled warning)	Severe belly pain radiating to the back, with or without vomiting — stop the medication and seek care
Gallbladder disease	Gallstones or inflammation, partly linked to rapid weight loss	Upper-right belly pain, fever, jaundice (yellowing of skin or eyes)
Acute kidney injury	Dehydration from vomiting or diarrhea can impair kidney function	Little or dark urine, dizziness, inability to keep fluids down
Low blood sugar	Mainly when combined with insulin or sulfonylureas in people with diabetes	Shakiness, sweating, confusion
Serious allergic reaction	Rare hypersensitivity (anaphylaxis or angioedema)	Face or throat swelling, trouble breathing — call 911
NAION (eye)	Possible association (not proven cause); EU classified "very rare" 2025; US FDA label not updated as of June 2026	Sudden vision loss or change in one or both eyes

Side-effect information is drawn from the FDA prescribing labels for Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) — the branded, FDA-approved medications — not from Nouri's compounded products. Information is current as of June 2026.

What is the boxed warning on Ozempic and Wegovy?

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — carry a boxed warning because they caused thyroid C-cell tumors in rodents at clinically relevant exposures. Whether this risk applies to humans is not determined. As a precaution, these medications are contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Disclose any thyroid history to your clinician before starting. (Wegovy FDA prescribing label)

This warning applies to both semaglutide and tirzepatide — it is a class effect, not specific to one brand. The boxed warning does not mean the drug causes thyroid cancer in most people; it means the risk exists in animals and caution is warranted in those with certain histories.

What other serious risks do GLP-1s carry?

Beyond the thyroid boxed warning, the FDA label for Wegovy and the FDA label for Zepbound include additional serious warnings:

• Pancreatitis: GLP-1s have been associated with pancreatitis (inflammation of the pancreas). The prescribing label advises stopping the medication and seeking care immediately for severe, persistent abdominal pain — particularly pain that radiates to the back, with or without vomiting. Do not push through this symptom.
• Gallbladder disease: Gallstones and acute gallbladder inflammation are labeled risks. Rapid weight loss itself can increase gallstone formation. Seek care for upper-right abdominal pain, fever, or jaundice.
• Acute kidney injury: Severe nausea, vomiting, or diarrhea can cause significant dehydration, which can impair kidney function. Staying hydrated — and seeking care if you cannot keep fluids down — reduces this risk.
• Low blood sugar (hypoglycemia): GLP-1s alone rarely cause hypoglycemia, but the risk increases substantially when combined with insulin or sulfonylureas. People with type 2 diabetes on these additional medications need to monitor closely.
• Severe GI reactions: Beyond typical nausea and vomiting, some people experience severe reactions requiring medical attention. These are uncommon but worth knowing.
• Serious allergic reactions: Anaphylaxis and angioedema are rare but have been reported. Seek emergency care immediately for swelling of the face or throat or difficulty breathing.
• Not for use in pregnancy: Both semaglutide and tirzepatide are contraindicated during pregnancy. Patients of childbearing potential should discuss contraception with their clinician.
• Diabetic retinopathy complications: People with a history of diabetic retinopathy may be at increased risk of worsening retinopathy. Discuss this with your clinician.

For comparison of side-effect profiles between the two main GLP-1 classes, see our guide to Mounjaro and Zepbound side effects.

What is NAION, and is it a confirmed risk?

Some observational research has reported a possible association between semaglutide use and non-arteritic anterior ischemic optic neuropathy (NAION) — a form of sudden, painless vision loss caused by reduced blood flow to the optic nerve. This is distinct from the branded medications' standard prescribing label warnings as of this writing.

In 2025, the European Medicines Agency (EMA) classified NAION as a "very rare" adverse event for semaglutide-containing medications. As of June 2026, the US FDA has not added NAION to the Wegovy prescribing label; the causal relationship remains under investigation and is currently characterized as an association, not a proven cause.

What to do: Report any sudden change in vision — including sudden loss of vision in one or both eyes — to a clinician promptly. This applies whether or not you are on a GLP-1.

When should you seek care immediately?

These symptoms warrant urgent medical attention — do not wait to see if they resolve:

• Severe abdominal pain, especially radiating to the back (possible pancreatitis — stop the medication)
• Persistent vomiting or inability to keep fluids down (risk of kidney injury from dehydration)
• Upper-right abdominal pain with fever or jaundice (possible gallbladder disease)
• Face or throat swelling, or difficulty breathing — call 911 immediately (anaphylaxis)
• Sudden vision loss or change in one or both eyes (possible NAION)
• Neck lump, hoarseness, or trouble swallowing (report to clinician; relevant to thyroid history)

None of these are common, but they are not symptoms to wait out. Having a clinician available when something feels wrong is part of responsible GLP-1 care.

What does long-term safety research show?

The most rigorous long-term safety evidence for semaglutide comes from large clinical trials of the FDA-approved branded molecules — not from Nouri's compounded product. In the STEP 1 trial (Wilding et al., NEJM 2021), serious adverse events were reported in a minority of participants and were generally consistent with the labeled warnings above. The SELECT trial (Lincoff et al., NEJM 2023) studied cardiovascular outcomes of semaglutide 2.4 mg over roughly 34 months in adults with overweight/obesity and established cardiovascular disease, finding a reduction in major cardiovascular events — which suggests that, for appropriate patients, the molecule's long-term benefit-risk profile can be favorable.

The STEP 4 trial (Rubino et al., JAMA 2021) showed that discontinuing semaglutide led to substantial weight regain within a year, underscoring that these medications require ongoing clinical management — reinforcing why monitoring and clinician oversight matter for the duration of treatment, not just at the start.

Long-term safety continues to be studied as these medications move into broader use. New signals (like the NAION data) are why staying connected to a prescriber — rather than self-managing — matters.

For more on what to expect week by week, see Starting Ozempic: What to Expect and How Long Do Ozempic Side Effects Last?

Related side-effect guides

• Ozempic & Semaglutide Side Effects (Complete List) — the hub for this cluster
• Mounjaro & Zepbound Side Effects
• Ozempic Nausea: How to Manage It
• How Long Do Ozempic Side Effects Last?

Why clinical oversight is especially important here

The serious risks above are exactly why GLP-1 therapy should be prescribed by a clinician who reviews your full history — contraindications (MTC, MEN 2, pancreatitis history), current medications (insulin, sulfonylureas), and any conditions that raise the risk of individual warnings. Ongoing access to your prescriber matters too: if a worrying symptom develops, you need to be able to reach someone who knows your file.

With Nouri, a U.S.-licensed physician reviews your intake before any prescription is issued. If something changes after you start, the Nouri Care Team is reachable for follow-up. Therapy is dispensed by Jungle Jim's Pharmacy, a named, state-licensed 503A compounding pharmacy in Fairfield, OH. Compounded GLP-1 medications are not FDA-approved and are not therapeutically equivalent to the brand-name drugs (Wegovy, Ozempic, Zepbound, Mounjaro).

The Nouri Promise: if you are not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans. Medication is prescribed only if clinically appropriate after a licensed provider reviews your intake. Not all applicants qualify.

Start your 5-minute assessment →
5-minute questionnaire · reviewed by a licensed clinician · Nouri Promise: full refund in 30 days on 3-month and 6-month plans · cancel anytime

Frequently asked questions

What are the serious side effects of Ozempic?

Rare but serious risks include thyroid C-cell tumors (a boxed warning based on rodent studies; human relevance not determined), pancreatitis, gallbladder disease, acute kidney injury from dehydration, low blood sugar (with certain diabetes medications), and serious allergic reactions. Most people do not experience these, but knowing the red-flag symptoms matters.

Does Ozempic cause thyroid cancer?

GLP-1s caused thyroid C-cell tumors in rodents; whether they do in humans is not determined, which is why there is a boxed warning. They are contraindicated if you or a family member has had medullary thyroid cancer (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Can Ozempic cause pancreatitis?

Pancreatitis is a labeled warning. Seek care immediately for severe, persistent abdominal pain (often radiating to the back), with or without vomiting — and stop the medication until evaluated.

Does Ozempic cause gallbladder problems?

Gallbladder disease and gallstones are labeled risks, partly linked to rapid weight loss. Warning signs include upper-right abdominal pain, fever, and jaundice (yellowing of the skin or eyes).

Is Ozempic safe long term?

For most people it is well tolerated, but it carries real warnings (thyroid, pancreatitis, gallbladder, kidney) and requires ongoing clinician oversight. Long-term cardiovascular safety was examined in the SELECT trial of semaglutide (Lincoff et al., NEJM 2023). Long-term safety continues to be studied; report any new or severe symptoms to your provider.

What is the Ozempic boxed warning?

It is a warning about the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on rodent studies (human relevance not determined). The medication is contraindicated with a personal or family history of MTC or MEN 2.

What are the serious side effects of Wegovy and Mounjaro?

They carry the same class warnings as Ozempic — the boxed thyroid C-cell tumor warning, pancreatitis, gallbladder disease, and acute kidney injury from dehydration. Tirzepatide (the molecule in Mounjaro and Zepbound) carries the same class-level serious risks.

Sources & references

1. Wegovy (semaglutide 2.4 mg) FDA prescribing label — boxed warning, Warnings and Precautions [Tier 1 — FDA]
2. Zepbound (tirzepatide) FDA prescribing label — Warnings and Precautions [Tier 1 — FDA]
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM, 2021. [Tier 1 — NEJM]
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM, 2023. [Tier 1 — NEJM]
5. Rubino DM et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. [Tier 1 — JAMA]
6. NIDDK. Prescription Medications to Treat Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. [Tier 1 — NIH/gov]
7. FDA. Human Drug Compounding. U.S. Food and Drug Administration. [Tier 1 — FDA]
8. European Medicines Agency. Product information update: NAION classified as a very rare adverse reaction for semaglutide products (2025). [Tier 2 — EU regulatory] Note: verify specific EMA product page before publishing.

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes. Last reviewed June 28, 2026.

This article is general information, not individual medical advice — talk to your clinician about your symptoms, and seek urgent care for the red-flag symptoms described here. Side-effect information comes from the FDA prescribing labels for the branded medications Wegovy (semaglutide) and Zepbound (tirzepatide); compounded semaglutide and tirzepatide were not studied in these trials, are not FDA-approved, and are not therapeutically equivalent to the brand-name drugs. GLP-1 medications carry a boxed warning for thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The NAION signal is an association as of June 2026 (EU classified "very rare"; US FDA label not yet updated — verify the current DailyMed Wegovy label before publishing). Ozempic®, Wegovy® and Rybelsus® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly; Nouri is not affiliated with either company. Information is current as of June 2026.